Novel antiplatelet agents in acute coronary syndrome (Q38257119)

1 September 2017

1 reference

title

Novel antiplatelet agents in acute coronary syndrome (English)

1 reference

1 September 2017

2

Dominick J Angiolillo

1 reference

1 September 2017

Francesco Franchi

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

7 October 2014

1 reference

Nature Reviews Cardiology

1 September 2017

published in

1 reference

1 September 2017

volume

12

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

30-47

1 reference

Update on acute coronary syndromes: the pathologists' view

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Mechanisms of acute coronary syndromes and their implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Basic principles of platelet biology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Thrombin and platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

A revised model of platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Protease-activated receptors in hemostasis, thrombosis and vascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Aspirin dose for the prevention of cardiovascular disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Bivalirudin started during emergency transport for primary PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Adverse haematological effects of ticlopidine. Prevention, recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

2013 ESC guidelines on the management of stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

New directions in antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Cangrelor: a review on pharmacology and clinical trial development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effect of platelet inhibition with cangrelor during PCI on ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patie

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Vorapaxar in the secondary prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Efficacy and safety of vorapaxar in patients with prior ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

New perspectives in antiplatelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (IS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous co

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Platelet function and genetic testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Response variability to P2Y12 receptor inhibitors: expectations and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Platelet function testing in contemporary clinical and interventional practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

"Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Oral factor Xa inhibitors for the long-term management of ACS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Transmission of a procoagulant signal from tissue factor-bearing cell to platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Thrombin functions during tissue factor-induced blood coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effects of ticlopidine or ticlopidine plus aspirin on platelet aggregation and ATP release in normal volunteers: why aspirin improves ticlopidine antiplatelet activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.156

Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations

31 March 2020

1 reference

12 December 2020

Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism.

1 reference

12 December 2020

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar

1 reference

12 December 2020

Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.

1 reference

12 December 2020

10.1038/NRCARDIO.2014.156

Identifiers

DOI

1 reference

1 September 2017

1 reference